* Ikena Oncology Inc IKNA.OQ reported a quarterly adjusted
loss
of 28 cents per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of -44 cents. The mean expectation of four analysts for the
quarter was for a loss of 35 cents per share. Wall Street
expected results to range from -42 cents to -27 cents per share.
* Reported revenue was zero; analysts expected zero.
* Ikena Oncology Inc's reported EPS for the quarter was a
loss
of 28 cents.
* The company reported a quarterly loss of $13.73 million.
* Ikena Oncology Inc shares had fallen by 1.2% this
quarter and
lost 17.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 10.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Ikena Oncology
Inc is $4.00
This summary was machine generated from LSEG data August 9 at
12:36 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.35 -0.28 Beat
Mar. 31 2024 -0.41 -0.33 Beat
Dec. 31 2023 -0.43 -0.47 Missed
Sep. 30 2023 -0.43 -0.40 Beat